Reading MBX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MBX free→Reading MBX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MBX free→NASDAQHealth CareBiotechnologySnapshot 2026-06-12
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, while management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, indicating challenges in the current market environment. If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting MBX and other Healthcare names. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $35.51. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.89x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.60. 6 raised, 0 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d. 92% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
No qualifying priorities for this snapshot. Check back after the next refresh.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$264.
How much price usually moves either way.
On a bad day, this stock has moved -$876.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,760.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for MBX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On June 12, 2026, the Company announced one-year data from the Phase 2 Avail™ and OLE clinical trials of canvuparatide in adult patients with chronic HP. The update is summarized below. Key Findings from the 12-Week Avail™ Phase 2 Trial and One-Year OLE Responder Rate • At 12 Weeks: As previously reported, 63% of canvuparatide-treated patients (30/48) achieved the primary composite endpoint compared with 31% of placebo-treated patients (5/16) (p=0.042). The primary endpoint was…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MBX MBX Biosciences, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 79 of 100 | full | low |
AMGN Amgen | Above typical Show detailsSector percentile: 75 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 96 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 82 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 4, 2026, MBX Biosciences, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). As further described under